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Abstract
Diabetes mellitus is a global epidemic that leads to multiple macrovascular and 
microvascular complications. The complex interrelated pathophysiological mecha-
nisms triggered by hyperglycemia underlie the development of diabetic retinopathy 
(DR). Proliferative diabetic retinopathy (PDR) is a microvascular complication, 
considered the main cause of irreversible blindness in patients of productive age in 
the world. On the other hand, diabetic macular edema (DME) remains the clinical 
feature most closely associated with vision loss. In general, both manifestations 
are due to an increase in inflammatory factors, such as specific pro-inflammatory 
prostaglandins, interleukins and angiogenic substances including vascular endothe-
lial growth factor (VEGF). Laser photocoagulation and VEGF inhibitors have been 
shown to be effective in the treatment of PDR and DME. Currently, randomized 
protocols suggest that VEGF inhibitors therapy could displace laser photocoagula-
tion in the treatment of PDR with and without the presence of DME. The ongoing 
discussion still prevails about the different treatment modalities for both retinal 
manifestations in real-world settings.
Keywords: proliferative diabetic retinopathy, diabetic macular edema, treatment 
algorithm, treatment guidelines, panretinal photocoagulation, antiangiogenic therapy
1. Introduction
Diabetic retinopathy (DR) is characterized by progressive damage to retinal 
capillaries causing retinal ischemia. In severe cases, it leads to DR, which threatens 
vision induced by angiogenesis [1]. Vascular endothelial growth factor (VEGF) is 
an important agent in the development and progression of DR and diabetic macular 
edema (DME) [2, 3].
The Early Treatment of DR (ETDRS) study showed that focal photocoagula-
tion of “clinically significant” DME reduces the risk of visual loss and increases the 
chances of visual improvement, decreases the frequency of persistent DME, and 
causes minor visual field losses [4]. Panretinal photocoagulation (PFC) has been the 
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standard treatment for proliferative diabetic retinopathy (PDR) since the DR study 
(DRS) demonstrated its benefit more than 40 years ago [5]. PFC has demonstrated 
permanent peripheral visual field loss and decreased night vision. On the other 
hand, it can exacerbate existing DME or increase its incidence. Different treatment 
alternatives in PDR should be considered [6].
DME can affect the macular center considering it as “with center-involving” 
(CI-DME) or it can respect the same, considering it as “non-center-involving” 
(NCI-DME). Anti-angiogenic (anti-VEGF) therapy in DME, has shown superior 
visual acuity results and acceptable risks compared to focal, grid, or untreated laser, 
and has also led to the observation that DR lesions can be reversed during treatment 
[7–14]. Anti-VEGF therapy is currently considered the first-line treatment for DME.
The objective of this chapter is to describe an algorithm in the treatment of PDR 
based on current publications that could be used in real-world scenarios and differ-
ent practice settings.
2. Current treatments in DME and PDR
According to the results of the DRCR.net Protocol S, at two years of follow-up, 
intravitreal ranibizumab (RBZ) achieved the result of non-inferiority in the change 
of best-corrected visual acuity (BCVA), which was no worse than in the PFC group 
treatment for PDR [15]. There were no statistically significant differences in BCVA 
between the RBZ and PFC groups, with the recognition that 53% of the PFC group 
received additional RBZ injections to treat DME and only 6% of the RBZ group 
required PFC. There was greater peripheral visual field loss (95% CI for differ-
ence, 213–531 dB) and more vitrectomies (PPV) were performed (95% CI for one 
difference, 4% -15%) in the PFC group compared to the RBZ group. In addition, 
RBZ-treated eyes were less likely to develop CI-DME causing visual impairment of 
20/32 or worse, similar to the 1-year results with aflibercept (AFB) in the CLARITY 
randomized clinical trial [16]. In the DRCR.net Protocol S, a greater number of 
patients in the PFC group developed DME (28 vs. 9). At 5-year results, the mean 
number of injections in the PFC group was 7.9 and 19.2 in the RBZ group. The mean 
final BCVA in both groups was 20/25. Despite the fact that at 2 years the PFC group 
presented a greater visual field loss, the decrease in the peripheral visual field 
progressed in both groups during the following 5 years of follow-up [17].
In a post hoc analysis of the DRCR.net Protocol T [18], after 2 years of follow-up, 
an improvement in DR severity was demonstrated by approximately 25% for AFB, 
22% for bevacizumab (BVZ) and 31% for RBZ in patients without proliferative-DR 
(NPDR) at baseline. This analysis also suggests a secondary benefit of DME after 
intravitreal AFB with respect to improvement in DR severity among patients who 
had PDR from baseline. Anti-VEGF therapy for DME improves the score of the 
DR severity scale (DRSS), evaluated in color fundus photos and can reduce the 
deterioration of the edema. Other randomized trials comparing anti-VEGF therapy 
and PFC in PDR, have demonstrated the non-inferiority of anti-VEGF over PFC 
in preventing PDR complications, at least during the first 2 years [19, 20]. Similar 
studies using ultra-wide-field (UWF) photographs and comparing them with 
ultra-wide-field fluorescein angiography (UWF-FAG) or wide field swept source 
optical coherent tomography (WF-SS-OCTA) in eyes with DR and DME [21, 22], 
conclude that after injections with anti-VEGF, improvement in the DRSS score can 
occur without vessel reperfusion or retinal capillary in UWF-FAG or WF-SS-OCTA. 
Therefore, the strong correlation between the number of lesions in DR and the 
areas of non-perfusion, established before any treatment, could no longer be rel-
evant after anti-VEGF therapy. These results should be taken into account in future 
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studies, in order to demonstrate an improvement in peripheral retinal perfusion in 
DR after anti-VEGF therapy.
3. Changing paradigms in the treatment of PDR
Taking into account specific scenarios of PDR proposed by Sun JK et al. [23], 
based on the results of the DRCR.net Protocol S [15] in addition to considering the 
different advantages of each treatment modality, we describe a treatment algorithm 
that could be used in real-world scenarios and in different practice settings.
3.1 PDR without DME
Both PFC and anti-VEGF therapy are feasible therapeutic options. Anti-VEGF 
therapy is effective in reversing retinal neovascularization (NV) and reducing the 
risk of developing DME. However, it may not be cost effective overall [24].
A. If starting PFC.
• Add anti-VEGF only in case NV significantly worsens (Table 1) and/or 
DME develops (Table 2).
B. If starting anti-VEGF, it is suggested to perform it according to the treatment 
algorithm proposed by Protocol S (Table 1).
• If NV worsens significantly, adding PFC should be considered.
• If NV does not require further anti-VEGF and during the “sustain stability” 
period DME develops, add focal macular laser or anti-VEGF (Table 2).
The advantages and disadvantages of treatment options should be considered, as 
well as the individual conditions of the patient.
3.2 PDR with NCI-DME
Anti-VEGF therapy has been accepted as a first-line treatment in DME, displac-
ing laser as a second-line therapy. Although some authors suggest the application 
of laser in NCI-DME [25–27], there are reports where the addition of conventional, 
subthreshold or micropulse laser does not add benefits to pharmacological mono-
therapy in any form of presentation [28–30].
1 Start with 6 monthly anti-VEGF injections (only with one exception), If the NV resolves after 4 or 
5 injections, the injections may be postponed.
2 After 6 months, continue the anti-VEGF injections if NV continues to progress or continues to 
improve; but defer injections if NV is stable at current visit and last 2 visits (“sustained stability”).
3 Resume anti-VEGF injections monthly if NV worsens after stopping injections. If “sustained 
stability” is achieved again, the injections can be postponed once more, but this requires at least 3 
consecutive anti-VEGF injections again; one administered for the initial state of progressive NV 
and 2 more if the NV remains stable.
PFC is given only if NV is substantially worse despite anti-VEGF. Onset or worsening of preretinal or vitreous 
hemorrhage is not necessarily classified as worsening of NV, unless bleeding precludes evaluation of NV.
Table 1. 
Algorithm for the treatment of PDR according to DRCR.net protocol S.
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A. If starting focal macular laser and PFC.
• Add anti-VEGF in case DME worsens (Table 2) and/or there is significant 
progression of NV (Table 1).
B. If starting anti-VEGF for DME (Table 2). PFC can be deferred since the same 
anti-VEGF may control both (DME and PDR).
• If DME does not require further anti-VEGF, NV status should be 
re-evaluated.
• If NV worsens significantly, it is suggested to decide on therapy according 
to Section 3.1 B (PDR without DME).
• In case of new DME activity, it is suggested to reactivate anti-VEGF therapy.
C. In the event that the DME has a poor or no response, several options should 
be considered (switching anti-VEGF, focal macular laser, dexamethasone 
implant, etc.).
Advantages and disadvantages of treatment options should be considered, as 
well as the individual conditions of the patient.
3.3 RDP with CI-DME
Anti-VEGF is considered first- line treatment in CI-DME. RBZ and AFB were 
highly effective in treating PDR [15, 16].
A. Anti-VEGF is recommended as first-line treatment in CI-DME (Table 2). PFC 
can be deferred since the same anti-VEGF may control both (DME and PDR).
• If DME does not require further anti-VEGF, NV status should be 
re-evaluated.
• If NV worsens significantly, it is suggested to decide on therapy according 
to Section 3.1 B (PDR without DME).
• In case of new DME activity, it is suggested to reactivate anti-VEGF 
therapy.
B. In the event that the DME has a poor or no response, several options should 
be considered (switching anti-VEGF, focal macular laser, dexamethasone 
implant, etc.).
Advantages and disadvantages of treatment options should be considered, as 
well as the individual conditions of the patient.
1 Start with 3 monthly ant-VEGF injections or until you achieve maximum improvement (loading 
phase).
2 After the loading phase, continue injecting according to reactive (Treat and Observe or Pro Re 
Nata) or proactive (Treat and Extend) behavior.
Table 2. 
Algorithm for the treatment of DME.
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3.4 High-risk PDR with or without vision- impairing DME
Eyes with high-risk PDR (i.e., ≥ ETDRS level 71) face the greatest risk of severe 
vision loss without intervention [4, 5]. Eyes with the most advanced forms of PDR 
have the largest relative benefit of RBZ compared with PRP when managing PDR. 
Also, RBZ was superior to PRP with respect to change in visual acuity over 2 years 
and prevention of vision-impairing CI-DME over 2 years, regardless of baseline 
characteristics [ 31]. On the other hand, combined therapy has shown benefits in 
the management of high-risk PDR.
• Anti-VEGF should be considered as monotherapy (Table 1).
• If NV worsens significantly, it is suggested to decide on therapy according to 
Section 3.1 B (PDR without DME).
Although anti-VEGF may be recommended as monotherapy in eyes with high-
risk PDR, complete PRP within the effective period of anti- VEGF agents might 
be recommended. Advantages and disadvantages of treatment options should be 
considered, as well as the individual conditions of the patient.
3.5 Worsening PDR
Worse baseline levels of DR severity (ETDRS scale) were associated with 
increased risk of worsening PDR (e.g., vitreous hemorrhage (VH), retinal detach-
ment (RD), angle neovascularization (ANV), or neovascular glaucoma (NVG)), 
regardless of treatment with PRP or RBZ. There were generally fewer PDR-
worsening events (e.g., VH, RD, ANV, or NVG) in eyes treated with RBZ versus PRP 
for PDR. Through 2-year, the cumulative probability of worsening PDR was 42% 
for PRP versus 34% for RBZ. The 2-year cumulative probability of VH was 39% for 
the PRP group and 30% for the RBZ group. The 2-year cumulative probability of 
RD was low in each treatment group at 11% for the PRP group and 5% for the RBZ 
group [20]. The fact that worsening PDR events were at higher rates in the PRP 
group, suggests that at least during the first two years of follow-up:
• Anti-VEGF should be considered as monotherapy (Table 1).
• If NV worsens significantly, it is suggested to decide on therapy according to 
Section 3.1 B (PDR without DME).
As in the eyes with high-risk PDR, complete PRP within the effective period 
of anti- VEGF agents might be recommended. Advantages and disadvantages of 
treatment options should be considered, as well as the individual conditions of the 
patient.
3.6 Vitrectomy for PDR
Eyes in both groups (RBZ or PRP) had visual loss associated with VH, being 
more severe in the PRP group. The protocol required investigators to wait at least 
8 weeks for a nonclearing VH before proceeding to vitrectomy (in the absence of 
known RD, iris NV, or ANV). VH was the primary indication for most PPV, 24 
(80%) procedures in the PRP group and 6 (75%) procedures in the RBZ group. 
Endolaser or indirect ophthalmoscopic laser during PPV were applied in 80% of 
procedures in the PRP group and in all procedures in the RBZ group. Only 1 eye in 
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the RBZ group received PRP independent of PPV. Possibly for convenience, the not 
masked investigators, decided to continue observing VH before proceeding to PPV 
in the RBZ group. The authors note that because VH, only 13% (7/52) in the RBZ 
group compared to 42% (29/69) in the PRP group underwent PPV at the end of 
2 years. Therefore, because VH was the main indication for surgery in both groups, 
the reduced incidence of VH in the RBZ group and the potential difference in VH 
severity may explain the finding that eyes in the PRP group were more likely to 
undergo vitrectomy [20]. Although several studies do not support the hypothesis 
that anti-VEGF administered to an eye with PDR, with or without high-risk features 
(but without macular-threatening traction at baseline), causes tractional RD (TRD) 
more often than eyes with PRP [7, 28, 32], we must consider the possibility of 
additional PPV in these patients.
4. Discussion
In clinical practice, treating PFC with one or more sessions may be sufficient 
to control PDR and no additional procedures are required. On the other hand, the 
cost of laser therapy is less expensive than anti-VEGF therapy and there is no risk 
of endophthalmitis or systemic adverse events [15]. The DRCR.net in a cost–ben-
efit analysis regarding RBZ or PFC monotherapy for PDR, noted that it was more 
appropriate to start with PFC for patients with PDR without associated DME and 
RBZ for those with DME at the time of treatment detection [33]. Therefore, the 
relative benefits of treating PDR with anti-VEGF versus PFC could be considered 
in a patient presenting with DME, where anti-VEGF therapy is generally necessary, 
as long as the patient adheres to treatment and is able to access it. In Mexico, as in 
some countries, it is possible to adopt the algorithm suggested by the DRCR.net 
Protocol S; however, the circumstances of patients and environment could modify 
the scheme. Likewise, the advantages and disadvantages of treatment options 
should be considered, in addition to socioeconomic conditions, adherence to treat-
ment, and access to “off-label” medications.
It is generally known that the pathogenesis and progression of DR involves 
changes in the vitreous structure and its relationship with the vitreoretinal interface 
[34–40]. A study whose objective was to evaluate the costs and usefulness of early 
PPV compared to PFC and intravitreal RBZ in PDR patients without DME, using a 
“decision analysis” based on the results of DRCR.net Protocol S at 2 years of treat-
ment for each scenario, concluded that PPV as a treatment strategy demonstrates 
a similar cost utility to treatment with PFC and a more favorable cost utility com-
pared to short-term intravitreal RBZ therapy [41]. This advantage over anti-VEGF is 
continuing when lifetime costs are considered. The safety of anti-VEGFs compared 
to primary PPV (without anti-VEGF) for persistent VH is being evaluated in the 
Protocol AB.
Currently, the PANORAMA study [42], a double-masked, randomized phase 
3 trial, the objective of which is to evaluate the efficacy and safety of intravitreal 
injection of AFB compared to sham therapy in improving moderate-to-severe 
NPDR in the absence of CI-DME, demonstrate at week 24 that AFB improved the 
severity of DR in patients with moderately severe to severe NPDR and suggests that 
anti-VEGF can reverse disease progression in these patients.
In turn, there is interest if steroid therapy in the treatment of DME can delay the 
progression or even improve DR. Corticosteroids inhibit the inflammatory pro-
cesses involved in DME, including the production of pro-inflammatory mediators, 
increased levels of VEGF, and the loss of endothelial tension-binding proteins [43, 
44]. There are clinical trials that have shown some benefit of intravitreal steroids 
7
Treatment Algorithm in Proliferative Diabetic Retinopathy. From Protocols to the Real World
DOI: http://dx.doi.org/10.5772/intechopen.99843
in the progression of DR. [12, 45] The “DR-Pro-Dex” study provides the first 
long-term evidence that the dexamethasone implant has the potential to not only 
delay the progression of DR and PDR but may also improve the severity of DR in 
24 months [46]. On the other hand, the results of the “TRADITION” study con-
clude that the implantation of dexamethasone at the end of a PPV in patients with 
TRD improves the severity of PDR and reduces the detachment rates [47].
In the case of DME, the little or no response of the anti-VEGF used and its 
relationship with persistent peripheral retinal ischemia require modifications in 
treatment. Alternatives should be considered such as: switching from anti-VEGF, 
intravitreal dexamethasone implant, additional PFC (peripheral retina), PPV or 
combining treatments. Although anti-VEGF monotherapy achieves stabilization of 
NV in PDR, adding PFC could result in a lower frequency of intravitreal applica-
tions, resulting in lower risks and costs for the patient.
In Figure 1, a flow-chart of treatment modalities for different presenting PDR 
scenarios is shown.
5. Conclusion
In general, the objective to achieve success in the treatment of PDR and DME is 
the inhibition of VEGF and pro-inflammatory factors, a condition that seems to be 
obtained more efficiently with pharmacological therapy in relation to retinal abla-
tion. Currently the indications for laser, intravitreal drug therapy (anti-VEGF’s and 
Figure 1. 
Treatment flow-chart in different presenting PDR scenarios. DME: Diabetic macular edema; DNCVH: Dense 
non-clearing vitreous hemorrhage; CI-DME: Center-involving diabetic macular edema. NCI-DME: Non-
center-involving diabetic macular edema; NV: New vessels; PDR: Proliferative diabetic retinopathy; PFC: 
Panretinal photocoagulation; TRD: Tractional retinal detachment threatening or involving macula; PPV: 
Pars plana vitrectomy. 1If starting anti-VEGF for DME, PFC can be deferred since the same anti-VEGF may 
control both DME and PDR. 2Consider factors such as risk of non-compliance, treatment cost, and treatment 
burden. 3Cases with TRD should not receive only anti-VEGF therapy due to increased traction progression 
risk. 4Anti-VEGF injection can be applied a few days before PPV is performed to decrease intraoperative and 
postoperative VH.
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anti-inflammatory steroids) and PPV are increasingly clear. Based on the results 
previously mentioned, anti-VEGF therapy appears to be emerging as first-line ther-
apy in PDR, as is currently suggested in the treatment of DME. Treatment regimens 
in patients with severe NPDR with or without DME, may be indifferent to those 
currently suggested in PDR patients with or without DME; including that early PPV 
is an alternative to prevent retinal complications of diabetic microvascular disease. 
This chapter suggests a treatment algorithm for PDR in different settings; however, 
we must not forget that both DME and PDR are different manifestations of DR and 
therefore must be assessed individually. Treatment decisions can be different for 
each manifestation and can be modified depending on its behavior. Several proto-
cols are currently being developed to more accurately understand the behavior of 
PDR and DME in different settings and to provide a more solid foundation for an 
effective and timely treatment scheme.
6. Protocols in progress
1. Protocol W: Safety and efficacy of AFB vs. observation in severe NPDR and 
BCVA ≥20/25 without DME and without previous treatment, to assess the  
appearance of edema or progression of retinopathy.
2. Protocol AA: To evaluate lesions in the peripheral DR and their association 
with the progression of retinopathy in patients with NPDR, without DME or 
previous treatment, comparing UWF images vs. standard photographs of the 
seven fields (ETDRS) in order to determine if UWF photographs contribute 
more information than conventional ones.
3. Protocol AB: Treatment of early PPV versus ARB in vitreous secondary to 
PDR is compared by evaluating BCVA at 6 months of treatment.
4. Protocol AD (PROMINENT): To assess whether treatment with pemfibrate 
(0.2 mg / 12 h orally) compared with placebo reduces the rate of worsening of 
DR in patients with type 2 diabetes and NPDR.
5. Protocol GEN: Create a genetic material and information on the clinical phe-
notype, which allows evaluating genetic susceptibility or resistance in DR and 
determining variants on key biomarkers in the development of DME and NV.
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